ArticleJournal of ovarian research2026
Additive value of whole abdomen FDG PET/MRI to standard whole body PET/CT for detection of peritoneal recurrence of ovarian cancer.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Deciphering the Pleiotropic Role ofCells · 2026Article
- The use of MRI in the diagnosis of ovarian cancer.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimPresence of peritoneal metastasis in ovarian cancer is one of the most important factors affecting the prognosis of the disease. In this study we aimed to investigate the additive value of dedicated abdomen MATERIAL-
methodsThis prospective study included 45 ovarian cancer patients with elevated serum Ca-125 levels during postoperative follow-up, all of whom underwent whole-body
resultsWith the addition of PET/MR imaging to PET/CT, peritoneal recurrence was detected in 35 patients (78%), whereas PET/CT alone detected recurrence in 26 patients (57%) (p = 0.012). The total number of regions with peritoneal uptake was 100 with PET/CT alone, but increased to 170 when PET/MRI was added (p < 0.001). Furthermore, distant organ metastases that were not detected on PET/CT were identified in 3 patients with the addition of PET/MRI. In our study, additional findings from PET/MRI led to changes in the treatment strategy for 15 patients (33%).
conclusionThe addition of dedicated abdominal PET/MRI to whole-body PET/CT enhances the detection of peritoneal metastases in patients with recurrent ovarian cancer and elevated Ca-125 levels. This combined imaging approach provides complementary information, improving diagnostic accuracy and aiding in the selection of optimal treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.